# OnCo record paper-golan-brca-pancreatic-platinum-survival-bjc-2014 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-golan-brca-pancreatic-platinum-survival-bjc-2014/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-golan-brca-pancreatic-platinum-survival-bjc-2014" ;
  schema:name "Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers"@en ;
  schema:description "Among 71 people with pancreatic cancer and an inherited BRCA mutation, those with advanced disease lived 22 months on platinum chemotherapy against 9 months on other drugs, the clinical hint that led to the POLO trial."@en ;
  schema:url <https://onco.cc/key-papers/paper-golan-brca-pancreatic-platinum-survival-bjc-2014/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1038/bjc.2014.418>, <https://pubmed.ncbi.nlm.nih.gov/25072261/> ;
  schema:sameAs <https://doi.org/10.1038/bjc.2014.418> ;
  schema:datePublished "2014"^^xsd:gYear ;
  schema:author "Golan T, Kanji ZS, Epelbaum R, et al." ;
  onco:related <https://onco.cc/biomarkers/brca-germline/> ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/brca-palb2-pdac/>, <https://onco.cc/cancers/metastatic-pdac/> ;
  onco:targets <https://onco.cc/targets/brca/> ;
  onco:drugs <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/gemcitabine-cisplatin/> ;
  onco:institutions <https://onco.cc/institutions/sheba/>, <https://onco.cc/institutions/princess-margaret/> ;
  onco:terms <https://onco.cc/terms/gbrca-mutation/> ;
  onco:people <https://onco.cc/people/talia-golan/> ;
  onco:journals <https://onco.cc/journals/british-journal-of-cancer/> .